|
VPRBP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.65973959207622E-14 |
| Normal-vs-Stage2 |
9.03789999950888E-07 |
| Normal-vs-Stage3 |
2.26485497023532E-14 |
| Normal-vs-Stage4 |
4.30289137653972E-12 |
| Stage1-vs-Stage2 |
4.265000E-01 |
| Stage1-vs-Stage3 |
1.095550E-01 |
| Stage1-vs-Stage4 |
7.159800E-02 |
| Stage2-vs-Stage3 |
6.892000E-02 |
| Stage2-vs-Stage4 |
5.529800E-02 |
| Stage3-vs-Stage4 |
7.527400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
3.94700000000414E-05 |
| Normal-vs-Asian |
2.52330001337953E-09 |
| Caucasian-vs-AfricanAmerican |
3.145400E-01 |
| Caucasian-vs-Asian |
8.813600E-01 |
| AfricanAmerican-vs-Asian |
4.133400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.33066907387547E-15 |
| Normal-vs-Female |
1.63324909152607E-12 |
| Male-vs-Female |
1.107960E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.19675405538555E-12 |
| Normal-vs-Age(41-60Yrs) |
1.48769885299771E-14 |
| Normal-vs-Age(61-80Yrs) |
6.15030248951598E-12 |
| Normal-vs-Age(81-100Yrs) |
5.805100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.197800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.868000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.980400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.637600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.930800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.545800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.455700E-02 |
| Classical-VS-Follicular |
8.679200E-01 |
| Classical-VS-Other |
6.300400E-02 |
| Classical-VS-Normal |
1.63025148935958E-12 |
| Tall-VS-Follicular |
1.003600E-01 |
| Tall-VS-Other |
3.621200E-01 |
| Tall-VS-Normal |
8.72629968284855E-10 |
| Follicular-VS-Other |
1.543430E-01 |
| Follicular-VS-Normal |
8.61089999304454E-09 |
| Other-VS-Normal |
3.96690000000754E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.30180327523522E-13 |
| Normal-vs-N1 |
1.82870385501133E-11 |
| N0-vs-N1 |
1.124990E-01 |
|
|
